[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-exacerbation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-exacerbation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100647916","ml-based-abpa-recurrence-prediction-and-clinical-utility-100647916",false,"NCT07714863","ML-Based ABPA Recurrence Prediction and Clinical Utility","Machine Learning-Based Prediction of Recurrence Risk in Allergic Bronchopulmonary Aspergillosis and Its Clinical Decision-Making Value: A Multicenter Study With External Validation","ABPA-ML","Inclusion Criteria:\n\n1. Aged between 18 and 80 years old.\n2. Consistent with the diagnostic consensus criteria for ABPA proposed by the ISHAM-ABPA Working Group.\n3. Patients in stable phase of ABPA: newly diagnosed treatment-naive patients or those with prior ABPA exacerbation who achieved at least 50% improvement in symptoms assessed by Likert scale or visual analogue scale (VAS) following initial therapy, accompanied by marked radiological improvement (≥50% reduction in pulmonary opacities) or a minimum 20% decline in serum total IgE level.\n\nExclusion Criteria:\n\n1. Concurrent malignant tumors or severe organ dysfunction involving the heart, brain, kidney and other vital organs.\n2. Complicated with severe underlying diseases, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease stage 5 (CKD 5), decompensated liver cirrhosis, etc.\n3. Immunocompromised status, such as human immunodeficiency virus (HIV) infection, long-term oral administration of glucocorticoids or immunosuppressive agents.\n4. Pregnant or breastfeeding women.\n5. Patients with missing core clinical data or incomplete medical records.","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","1 Year","OBSERVATIONAL","This multicenter bidirectional cohort study aims to develop and externally validate a machine learning model for predicting the risk of acute exacerbation within 1 year in patients with allergic bronchopulmonary aspergillosis (ABPA) during the stable phase, and further to evaluate the model's practical value in risk stratification and clinical decision-making.\n\nAll patients diagnosed with ABPA according to the ISHAM 2024 criteria will be assigned to either the acute exacerbation group or the non-exacerbation group based on whether they experience an acute exacerbation within 1 year. Enrolled participants will be randomly divided into a training set and an internal validation set. During the feature selection phase, univariate analysis, collinearity diagnostics, feature importance ranking derived from nine machine learning algorithms, and expert consensus are comprehensively applied, ultimately leading to the development of 12 independent machine learning models.\n\nModel performance is assessed using the receiver operating characteristic (ROC) curve and its area under the curve (AUC), sensitivity, specificity, F1-score, calibration curve, and decision curve analysis. In addition, external validation further enhances the credibility of the model. To improve clinical interpretability, the SHAP method is employed to quantify the contribution of each feature, and an interactive nomogram is constructed to facilitate clinical application.\n\nAll participants will be followed up for 12 months, during which regular clinical and laboratory evaluations will be performed.",[26,27,28,29,30],"ABPA","Allergic Bronchopulmonary Aspergillosis","Allergic Bronchopulmonary Aspergillosis (ABPA)","Acute Exacerbation","Machine Learning",[26,32,30],"Acute exacerbation","RECRUITING","2026-07-14",{"date":36,"type":37},"2026-07-20","ACTUAL",{"date":39,"type":37},"2021-01-01",{"date":41,"type":21},"2028-12-31",{"name":43,"class":44},"Qianfoshan Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":65,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100640851","safety-of-bronchoscopy-in-patients-with-interstitial-lung-disease-100640851","NCT07627594","Safety of Bronchoscopy in Patients With Interstitial Lung Disease","Safety of Bronchoscopy in Patients With Interstitial Lung Disease: A Prospective, Observational, Multicentre, International Study","SaBrILD","Inclusion Criteria:\n\n* Consecutive adult (≥18 years old) patients with suspected or confirmed ILD who need to undergo bronchoscopy as part of their routine clinical practice,\n* Patients able to understand and sign an informed consent\n\nExclusion Criteria:\n\n* Patients who refused the study partecipation;\n* Patients with contraindications to bronchoscopy",{"count":55,"type":21},427,"Bronchoscopy is an essential technique, routinely used in the differential diagnosis workup of many Interstitial Lung Diseases (ILDs) and in referral centres is a common procedure. Bronchoalveolar lavage (BAL), bronchial and transbronchial biopsies with forceps and cryoprobes, and lymph node sampling with endosonography represent the most used sampling techniques in these patients. However, patients with ILDs refer to medical attention in a wide range of clinical conditions from mild functional impairment, with absent or few respiratory symptoms, to severe lung involvement with low exercise tolerance and\u002For chronic respiratory failure. In these patients, a balance between benefits and risk, i.e. to the safety and diagnostic utility of bronchoscopy should be always carefully evaluated. Moreover, there is a wide variability in adverse events entity and frequency depending by procedures performed during bronchoscopy.\n\nDespite its crucial utility, only few data are available in the literature on the safety of bronchoscopy in patients with ILDs and limited data on the utility and safety of this sampling technique are present in patients with AE-ILDs.\n\nThe primary aim of this study is to assess the overall rate of complications occurring within 24 hours after bronchoscopy. Study rate and type of complications occurring during the endoscopic procedure, within 30 days after bronchoscopy, in patients with AE-ILDs, among fibrotic Vs non-fibrotic ILD, and according to each employed sampling technique will be also recorded.",[58,59,60,29,61,62,63,64],"Interstitial Lung Disease (ILD)","Bronchoscopy","Bronchoalveolar Lavage (BAL)","Cryobiopsy","Transbronchial Biopsy","Endosonography","Pulmonary Fibrosis",[66,67,68,69,70,71,72],"ILD","BAL","acute exacerbation","cryobiopsy","transbronchial biopsy","interstitial lung disease","pulmonary fibrosis","NOT_YET_RECRUITING","2026-05-29",{"date":76,"type":37},"2026-06-04",{"date":78,"type":21},"2026-06-01",{"date":80,"type":21},"2028-05-30",{"name":82,"class":44},"University of Milan",11]